161 related articles for article (PubMed ID: 1359119)
1. Biochemical and functional identification of a novel dopamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis.
Nisoli E; Tonello C; Memo M; Carruba MO
J Pharmacol Exp Ther; 1992 Nov; 263(2):823-9. PubMed ID: 1359119
[TBL] [Abstract][Full Text] [Related]
2. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
3. Characterization of monoaminergic receptors in hypothalamic nuclei mediating feeding behavior in rats.
Carruba MO; Nisoli E; Garosi V; Pizzi M; Memo M; Spano P
J Pharmacol Exp Ther; 1991 Oct; 259(1):124-30. PubMed ID: 1681082
[TBL] [Abstract][Full Text] [Related]
4. Light modulates dopamine-regulated Walsh inhibitor activity and dopamine-dependent cyclic AMP accumulation in the rabbit retina.
Nowak JZ; Zawilska J; Sek B; Schorderet M
Pol J Pharmacol Pharm; 1990; 42(5):457-70. PubMed ID: 1983030
[TBL] [Abstract][Full Text] [Related]
5. Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes.
Nisoli E; Tonello C; Landi M; Carruba MO
Mol Pharmacol; 1996 Jan; 49(1):7-14. PubMed ID: 8569714
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
7. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Tang L; Todd RD; Heller A; O'Malley KL
J Pharmacol Exp Ther; 1994 Jan; 268(1):495-502. PubMed ID: 8301592
[TBL] [Abstract][Full Text] [Related]
9. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
[TBL] [Abstract][Full Text] [Related]
10. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
Beninger RJ; Mazurski EJ; Hoffman DC
Pol J Pharmacol Pharm; 1991; 43(6):507-28. PubMed ID: 1687945
[TBL] [Abstract][Full Text] [Related]
11. Effect of dopamine receptor activation on ganglionic transmission and cyclic AMP levels in the stellate ganglia and renal arteries of the dog.
Sabouni MH; Alkadhi KA; Lokhandwala MF
J Pharmacol Exp Ther; 1987 Jan; 240(1):93-8. PubMed ID: 2879905
[TBL] [Abstract][Full Text] [Related]
12. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
13. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization.
Godbout R; Mantz J; Pirot S; Glowinski J; Thierry AM
J Pharmacol Exp Ther; 1991 Aug; 258(2):728-38. PubMed ID: 1865369
[TBL] [Abstract][Full Text] [Related]
15. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
[TBL] [Abstract][Full Text] [Related]
16. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Enjalbert A; Bockaert J
Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical regulation of dopamine receptors in transfected 293 cells.
Filtz TM; Artymyshyn RP; Guan W; Molinoff PB
Mol Pharmacol; 1993 Aug; 44(2):371-9. PubMed ID: 8102783
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
Sesack SR; Bunney BS
J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
[TBL] [Abstract][Full Text] [Related]
20. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells.
Barton AC; Black LE; Sibley DR
Mol Pharmacol; 1991 May; 39(5):650-8. PubMed ID: 1674585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
